Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies

Authors

Institutions

Publication Details

Journal
Lung Cancer
Published
2025-10-09
DOI
https://doi.org/10.1016/j.lungcan.2025.108793
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies

Myung‐Ju Ahn, Nobuyuki Yamamoto, Takayuki Asato, Pingkuan Zhang et al.
Lung Cancer
Lung Cancer Treatments and Mutations
article

Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies

Myung‐Ju Ahn, Nobuyuki Yamamoto, Takayuki Asato, Pingkuan Zhang, Tony S.K. Mok, Edward S. Kim, Kentarou Kudou, Makoto Nishio, Tatsuya Yoshida, Sylvie Vincent, Hui Yang, Xin Tong
article en

Abstract

No abstract available for this paper.
Lung CancerVol. 209
City Of Hope National Medical Center (US), Chinese University of Hong Kong (HK), Wakayama Medical University (JP), Samsung Medical Center (KR), National Cancer Centre Japan (JP), National Cancer Center (US), The Cancer Institute Hospital (JP), Takeda (United States) (US), Japanese Foundation For Cancer Research (JP), Takeda (Japan) (JP)
Openalex Percentile: Top 59%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.